WS15.05 Improvements in Structural Lung Disease in People with CF Aged 12 and above on Elexacaftor/tezacaftor/ivacaftor Are Sustained for Up to Two Years
Journal of Cystic Fibrosis(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
Journal of Cystic Fibrosis(2024)